Both Adzenys and Adderall are stimulant-based drugs that target neurotransmitters in the brain, but there are some ...

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.

FORT-2 is a phase 1b/2 non-randomized clinical trial conducted in 30 centers across Asia, Europe and North America. It is the first clinical trial to evaluate the safety, tolerability and the ...

Chronic pain affects millions of individuals worldwide, significantly impacting their quality of life and daily function.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...